180 related articles for article (PubMed ID: 11993610)
1. Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks.
Stark R; Dahlöf C; Haughie S; Hettiarachchi J;
Cephalalgia; 2002 Feb; 22(1):23-32. PubMed ID: 11993610
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison.
Diener HC; Jansen JP; Reches A; Pascual J; Pitei D; Steiner TJ;
Eur Neurol; 2002; 47(2):99-107. PubMed ID: 11844898
[TBL] [Abstract][Full Text] [Related]
3. Eletriptan for acute migraine.
Smith LA; Oldman AD; McQuay HJ; Moore RA
Cochrane Database Syst Rev; 2001; (3):CD003224. PubMed ID: 11687056
[TBL] [Abstract][Full Text] [Related]
4. WITHDRAWN: Eletriptan for acute migraine.
Smith LA; Oldman AD; McQuay HJ; Moore RA
Cochrane Database Syst Rev; 2007 Jul; 2001(1):CD003224. PubMed ID: 17636718
[TBL] [Abstract][Full Text] [Related]
5. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee.
Goadsby PJ; Ferrari MD; Olesen J; Stovner LJ; Senard JM; Jackson NC; Poole PH
Neurology; 2000 Jan; 54(1):156-63. PubMed ID: 10636142
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States.
Sheftell F; Ryan R; Pitman V;
Headache; 2003 Mar; 43(3):202-13. PubMed ID: 12603638
[TBL] [Abstract][Full Text] [Related]
7. Consistency of eletriptan in treating migraine: Results of a randomized, within-patient multiple-dose study.
Almas M; Tepper SJ; Landy S; Schweizer E; Ramos E
Cephalalgia; 2014 Feb; 34(2):126-35. PubMed ID: 23946318
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine.
Garcia-Ramos G; MacGregor EA; Hilliard B; Bordini CA; Leston J; Hettiarachchi J
Cephalalgia; 2003 Nov; 23(9):869-76. PubMed ID: 14616928
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine.
Steiner TJ; Diener HC; MacGregor EA; Schoenen J; Muirheads N; Sikes CR
Cephalalgia; 2003 Dec; 23(10):942-52. PubMed ID: 14984226
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of eletriptan 20 mg, 40 mg and 80 mg in Japanese migraineurs.
Eletriptan Steering Committee in Japan
Cephalalgia; 2002 Jul; 22(6):416-23. PubMed ID: 12133040
[TBL] [Abstract][Full Text] [Related]
11. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan.
Färkkilä M; Olesen J; Dahlöf C; Stovner LJ; ter Bruggen JP; Rasmussen S; Muirhead N; Sikes C
Cephalalgia; 2003 Jul; 23(6):463-71. PubMed ID: 12807526
[TBL] [Abstract][Full Text] [Related]
12. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial.
Dowson AJ; Massiou H; Laínez JM; Cabarrocas X
Cephalalgia; 2002 Jul; 22(6):453-61. PubMed ID: 12133045
[TBL] [Abstract][Full Text] [Related]
13. Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study.
Sandrini G; Färkkilä M; Burgess G; Forster E; Haughie S;
Neurology; 2002 Oct; 59(8):1210-7. PubMed ID: 12391349
[TBL] [Abstract][Full Text] [Related]
14. Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial.
Winner P; Linder SL; Lipton RB; Almas M; Parsons B; Pitman V
Headache; 2007 Apr; 47(4):511-8. PubMed ID: 17445100
[TBL] [Abstract][Full Text] [Related]
15. Comparing the efficacy of eletriptan for migraine in women during menstrual and non-menstrual time periods: a pooled analysis of randomized controlled trials.
Bhambri R; Martin VT; Abdulsattar Y; Silberstein S; Almas M; Chatterjee A; Ramos E
Headache; 2014 Feb; 54(2):343-54. PubMed ID: 24256184
[TBL] [Abstract][Full Text] [Related]
16. Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing.
Brandes JL; Kudrow D; Cady R; Tiseo PJ; Sun W; Sikes CR
Cephalalgia; 2005 Sep; 25(9):735-42. PubMed ID: 16109056
[TBL] [Abstract][Full Text] [Related]
17. [Spanish contribution to the clinical development of eletriptan: an analysis of controlled studies].
Pascual J; Leira R; Lainez JM; Liaño H; Díez-Tejedor E; Navarro A; Jiménez D; Ezpeleta D; Mateos V; Madrigal M; Palacios G;
Neurologia; 2004 Oct; 19(8):414-9. PubMed ID: 15470580
[TBL] [Abstract][Full Text] [Related]
18. Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review.
Mathew NT; Hettiarachchi J; Alderman J
Headache; 2003 Oct; 43(9):962-74. PubMed ID: 14511273
[TBL] [Abstract][Full Text] [Related]
19. Patient preference for eletriptan 80 mg versus subcutaneous sumatriptan 6 mg: results of a crossover study in patients who have recently used subcutaneous sumatriptan.
Schoenen J; Pascual J; Rasmussen S; Sun W; Sikes C; Hettiarachchi J
Eur J Neurol; 2005 Feb; 12(2):108-17. PubMed ID: 15679698
[TBL] [Abstract][Full Text] [Related]
20. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study.
Pascual J; Falk RM; Piessens F; Prusinski A; Docekal P; Robert M; Ferrer P; Luria X; Segarra R; Zayas JM
Cephalalgia; 2000 Jul; 20(6):588-96. PubMed ID: 11075844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
